Evidence map›Paper›PMID 26353087›Full record

ArticlePLoS neglected tropical diseases2015

Mapping of Bancroftian Filariasis in Cameroon: Prospects for Elimination.

Hugues C Nana-Djeunga, Jules B Tchatchueng-Mbougua, Jean Bopda, Steve Mbickmen-Tchana, Nathalie Elong-Kana, Etienne Nnomzo'o, Julie Akame, Ann Tarini, Yaobi Zhang, Flobert Njiokou and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Hugues C Nana-DjeungaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon; Parasitology and Ecology Laboratory, Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon.
Jules B Tchatchueng-MbouguaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Jean BopdaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Steve Mbickmen-TchanaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Nathalie Elong-KanaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Etienne Nnomzo'oNTD Control Program, Ministry of Public Health, Yaoundé, Cameroon.
Julie AkameHelen Keller International, Yaoundé, Cameroon.
Ann TariniHelen Keller International, Yaoundé, Cameroon.
Yaobi ZhangHelen Keller International, Regional Office for Africa, Dakar, Senegal.
Flobert NjiokouParasitology and Ecology Laboratory, Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon.
Joseph KamgnoCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Université de Yaoundé I · CMHelen Keller International · CMHelen Keller International · USMinistry of Public Health · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphatic filariasis (LF) is one of the most debilitating neglected tropical diseases (NTDs). It still presents as an important public health problem in many countries in the tropics. In Cameroon, where many NTDs are endemic, only scant data describing the situation regarding LF epidemiology was available. The aim of this study was to describe the current situation regarding LF infection in Cameroon, and to map this infection and accurately delineate areas where mass drug administration (MDA) was required. METHODOLOGY: The endemicity status and distribution of LF was assessed in eight of the ten Regions of Cameroon by a rapid-format card test for detection of W. bancrofti antigen (immunochromatographic test, ICT). The baseline data required to monitor the effectiveness of MDA was collected by assessing microfilariaemia in nocturnal calibrated thick blood smears in sentinel sites selected in the health districts where ICT positivity rate was ≥ 1%. PRINCIPAL

findingsAmong the 120 health districts visited in the eight Regions during ICT survey, 106 (88.3%) were found to be endemic for LF (i.e. had ICT positivity rate ≥ 1%), with infection rate from 1.0% (95% CI: 0.2-5.5) to 20.0% (95% CI: 10-30). The overall infection rate during the night blood survey was 0.11% (95% CI: 0.08-0.16) in 11 health districts out of the 106 surveyed; the arithmetic mean for microfilaria density was 1.19 mf/ml (95% CI: 0.13-2.26) for the total population examined. CONCLUSION/SIGNIFICANCE: ICT card test results showed that LF was endemic in all the Regions and in about 90% of the health districts surveyed. All of these health districts qualified for MDA (i.e. ICT positivity rate ≥ 1%). Microfilariaemia data collected as part of this study provided the national program with baseline data (sentinel sites) necessary to measure the impact of MDA on the endemicity level and transmission of LF important for the 2020 deadline for global elimination.

Indexed as

Endemic DiseasesAdolescentAdultAgedAged, 80 and overCameroonChildChild, PreschoolChromatography, AffinityElephantiasis, FilarialFemaleHumansMaleMiddle AgedTopography, MedicalYoung Adult

Identifiers

PMID26353087
PMCPMC4564182
OpenAlexW1884384811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.